Our discussion with Christine Chambers has been going on for only a little more than 5 minutes when she tells us that she remembers sitting on the steps of a London flat years ago while contemplating life’s many twists and turns.
It seems that the accommodation—which she had only recently acquired and unquestionably counted as a milestone in life—had with little warning come to present a dilemma.
At that time back in 2007, when Chambers was working as a financial analyst inside the UK operations of Seattle, Washington–based RealNetworks, the company suddenly offered her a promotion to work within its US operations.
The treasured flat became toast.
“Six weeks later, I was on a plane headed to the U.S.—and I think that this speaks at least a little to my nature of being adaptable and open in terms of welcoming opportunities that have arisen,” comments Chambers, who would first join RealNetworks stateside in its Washington, D.C.–area outpost before receiving an invitation from the company’s CFO in 2010 to relocate to Seattle to join its corporate offices.
Eleven years later, Chambers would be appointed CFO of RealNetworks. Of course, career paths are seldom linear, and indeed Chambers’s CFO appointment at RealNetworks would arrive only after a 3-year stint as an FP&A leader with Rosetta Stone and two more as a planning and budgeting executive at the Bill and Melinda Gates Foundation.
“I have always really leaned into my network for opportunities,” remarks Chambers, as she stops to consider the different doors that she has been able to swing open along the way.
“By learning within my network," she observes, "I have sought to understand the dynamics within companies and the challenges and opportunities that they bring.”
The power of Chambers’s network was no doubt in play when PetMeds CEO Matt Hulett, a former colleague at Rosetta Stone as well RealNetworks, announced her appointment as PetMeds CFO in August 2022.
Says Chambers: “Matt and I very much understand the dynamics and challenges faced by organizations that have large, addressable markets and may have undervalued assets that need to be turned around. We have seen this both at Rosetta Stone and now at PetMeds.” –Jack Sweeney
